Enveda Biosciences, a Colorado-based biotech company that leverages the power of AI to develop new plant-based medicines, has secured $55M in a series B2 financing round to advance its breakthrough AI-powered drug discovery platform. The latest funding round was spearheaded by new investors Premji Invest and Lingotto Investment Fund, with participation from Microsoft and The Enveda Biosciences will use the new capital to accelerate its AI-powered drug discovery platform and advance novel treatment candidates to clinical trials.
read more..